Amyloid and tau pathology of familial Alzheimer’s disease APP/PS1 mouse model in a senescence phenotype background (SAMP8)

Age

Volumn 37, Issue 1, 2015, Pages

  Porquet, D ^a,d   Andres Benito P ^a   Grinan Ferre C ^a,d   Camins, A ^a,d   Ferrer, I ^c,d   Canudas, A M ^a,d   Del Valle, J ^a,b,d   Pallàs, Mercè ^a,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Aging; Cognitive impairment; Familial Alzheimer s disease (fAD); Tau hyperphosphorylation; Amyloid

Indexed keywords

AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; BETA SECRETASE; CATALASE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; INDUCIBLE NITRIC OXIDE SYNTHASE; PRESENILIN 1; SERINE; SUPEROXIDE DISMUTASE; TAU PROTEIN; TAURINE; PRESENILIN 1, MOUSE;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; FAMILIAL DISEASE; FEMALE; HIPPOCAMPUS; HYPERPHOSPHORYLATION; MALE; MOUSE; MOUSE STRAIN; NEUROPATHOLOGY; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SENESCENCE; SENESCENCE ACCELERATED MOUSE; SENESCENCE ACCELERATED MOUSE PRONE 8; SIGNAL TRANSDUCTION; SPECIES COMPARISON; TRANSGENIC MOUSE; WEIGHT GAIN; AGING; ANIMAL; DISEASE MODEL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; PHENOTYPE; PRESENILIN-1; TAU PROTEINS;

EID: 84965085419     PISSN: 01619152     EISSN: 15744647     Source Type: Journal    
DOI: 10.1007/s11357-015-9747-3     Document Type: Article

References (68)

1. Agarwal A, Saleh RA, Bedaiwy MA (2003) Role of reactive oxygen species in the pathophysiology of human reproduction. Fertil Steril 79:829–43
2. Ahn K, Shelton CC, Tian Y et al (2010) Activation and intrinsic gamma-secretase activity of presenilin 1. Proc Natl Acad Sci U S A 107:21435–40. doi:10.1073/pnas.1013246107
3. Antunes M, Biala G (2012) The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 13:93–110. doi:10.1007/s10339-011-0430-z
4. Aso E, Lomoio S, López-González I et al (2012) Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer’s disease. Brain Pathol 22:636–53. doi:10.1111/j.1750-3639.2011.00560.x
5. Aubele T, Kaufman R, Montalmant F, Kritzer MF (2008) Effects of gonadectomy and hormone replacement on a spontaneous novel object recognition task in adult male rats. Horm Behav 54:244–52. doi:10.1016/j.yhbeh.2008.04.001
6. Bahrick LE, Hernandez-Reif M, Pickens JN (1997) The effect of retrieval cues on visual preferences and memory in infancy: evidence for a four-phase attention function. J Exp Child Psychol 67:1–20. doi:10.1006/jecp.1997.2399
7. Bancher C, Brunner C, Lassmann H et al (1989) Accumulation of abnormally phosphorylated τ precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain Res 477:90–99
8. Borchelt DR, Thinakaran G, Eckman CB et al (1996) Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17:1005–13
9. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–59
10. Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 16:271–278
11. Braak H, Braak E (1998) Evolution of neuronal changes in the course of Alzheimer’s disease. J Neural Transm Suppl 53:127–40
12. Butterfield DA, Poon HF (2005) The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer’s disease. Exp Gerontol 40:774–83. doi:10.1016/j.exger.2005.05.007
13. Campion D, Dumanchin C, Hannequin D et al (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 65:664–70. doi:10.1086/302553
14. Canudas AM, Gutierrez-Cuesta J, Rodríguez MI et al (2005) Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mech Ageing Dev 126:1300–1304. doi:10.1016/j.mad.2005.07.008
15. Casadesús G, Gutierrez-Cuesta J, Lee H-G et al (2012) Neuronal cell cycle re-entry markers are altered in the senescence accelerated mouse P8 (SAMP8). J Alzheimers Dis 30:573–83. doi:10.3233/JAD-2012-120112
16. Chávez-Gutiérrez L, Tolia A, Maes E et al (2008) Glu(332) in the Nicastrin ectodomain is essential for gamma-secretase complex maturation but not for its activity. J Biol Chem 283:20096–105. doi:10.1074/jbc.M803040200
17. Codita A, Winblad B, Mohammed AH (2006) Of mice and men: more neurobiology in dementia. Curr Opin Psychiatry 19:555–63. doi:10.1097/01.yco.0000245757.06374.6a
18. Currais A, Prior M, Dargusch R et al (2013) Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer’s disease transgenic mice. Aging Cell. doi:10.1111/acel.12185
19. Del Valle J, Duran-Vilaregut J, Manich G et al (2010) Early amyloid accumulation in the hippocampus of SAMP8 mice. J Alzheimers Dis 19:1303–15. doi:10.3233/JAD-2010-1321
20. Del Valle J, Duran-Vilaregut J, Manich G et al (2011) Cerebral amyloid angiopathy, blood-brain barrier disruption and amyloid accumulation in SAMP8 mice. Neurodegener Dis 8:421–9. doi:10.1159/000324757
21. Dewachter I, van Dorpe J, Spittaels K et al (2000) Modeling Alzheimer’s disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp Gerontol 35:831–841. doi:10.1016/S0531-5565(00)00149-2
22. Díaz-Moreno M, Hortigüela R, Gonçalves A et al (2013) Aβ increases neural stem cell activity in senescence-accelerated SAMP8 mice. Neurobiol Aging 34:2623–38. doi:10.1016/j.neurobiolaging.2013.05.011
23. Enserink M (1998) First Alzheimer’s diagnosis confirmed. Science 279:2037
24. Feng Y, Wang X (2012) Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev 2012:472932. doi:10.1155/2012/472932
25. Flood JF, Morley JE (1998) Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev 22:1–20
26. Fukumori A, Fluhrer R, Steiner H, Haass C (2010) Three-amino acid spacing of presenilin endoproteolysis suggests a general stepwise cleavage of gamma-secretase-mediated intramembrane proteolysis. J Neurosci 30:7853–62. doi:10.1523/JNEUROSCI. 1443-10.2010
27. Games D, Adams D, Alessandrini R et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523–7. doi:10.1038/373523a0
28. Games D, Buttini M, Kobayashi D et al (2006) Mice as models: transgenic approaches and Alzheimer’s disease. J Alzheimers Dis 9:133–49
29. Gandy S, DeKosky ST (2013) Toward the treatment and prevention of Alzheimer’s disease: rational strategies and recent progress. Annu Rev Med 64:367–83. doi:10.1146/annurev-med-092611-084441
30. Glenner GG, Wong CW (1984) Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122:1131–5
31. Grady CL (2001) Altered brain functional connectivity and impaired short-term memory in Alzheimer’s disease. Brain 124:739–756. doi:10.1093/brain/124.4.739
32. Guimerà A, Gironès X, Cruz-sánchez FF (2002) Actualización sobre la patología de la enfermedad de Alzheimer. Rev Esp Patol 35:21–48
33. Guo Q, Li H, Cole AL et al (2013) Modeling Alzheimer’s disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau. PLoS One 8:e80706. doi:10.1371/journal.pone.0080706
34. Harvey RJ (2003) The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 74:1206–1209. doi:10.1136/jnnp.74.9.1206
35. Iqbal K, Grundke-Iqbal I (2008) Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12:38–55. doi:10.1111/j.1582-4934.2008.00225.x
36. Irizarry MC, Soriano F, McNamara M et al (1997) Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17:7053–7059
37. Itzhaki RF (1994) Possible factors in the etiology of Alzheimer’s disease. Mol Neurobiol 9:1–13. doi:10.1007/BF02816099
38. Knappenberger KS, Tian G, Ye X et al (2004) Mechanism of gamma-secretase cleavage activation: is gamma-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop? Biochemistry 43:6208–18. doi:10.1021/bi036072v
39. Koedam ELGE, Lauffer V, van der Vlies AE et al (2010) Early- versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 19:1401–8. doi:10.3233/JAD-2010-1337
40. Kumar VB, Franko M, Banks WA et al (2009) Increase in presenilin 1 (PS1) levels in senescence-accelerated mice (SAMP8) may indirectly impair memory by affecting amyloid precursor protein (APP) processing. J Exp Biol 212:494–8. doi:10.1242/jeb.022780
41. Li YM, Xu M, Lai MT et al (2000) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689–94. doi:10.1038/35015085
42. Lok K, Zhao H, Shen H, Lok K, Zhao H, Shen H et al (2013a) Characterization of the APP/PS1 mouse model of Alzheimer’s disease in senescence accelerated background. Neurosci Lett 557(Pt B):84–9. doi:10.1016/j.neulet.2013.10.051
43. Lok K, Zhao H, Zhang C et al (2013b) Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer’s disease. J Neurol Sci 335:145–54. doi:10.1016/j.jns.2013.09.018
44. Lucas JJ, Hernández F, Gómez-Ramos P et al (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20:27–39. doi:10.1093/emboj/20.1.27
45. Manich G, Mercader C, del Valle J et al (2011) Characterization of amyloid-β granules in the hippocampus of SAMP8 mice. J Alzheimers Dis 25:535–46. doi:10.3233/JAD-2011-101713
46. Markowska AL, Spangler EL, Ingram DK (1998) Behavioral assessment of the senescence-accelerated mouse (SAM P8 and R1). Physiol Behav 64:15–26
47. McGowan E, Sanders S, Iwatsubo T et al (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 6:231–44. doi:10.1006/nbdi.1999.0243
48. Miyamoto M, Kiyota Y, Yamazaki N et al (1986) Age-related changes in learning and memory in the senescence-accelerated mouse (SAM). Physiol Behav 38:399–406
49. Miyamoto M, Kiyota Y, Nishiyama M, Nagaoka A (1992) Senescence-accelerated mouse (SAM): age-related reduced anxiety-like behavior in the SAM-P/8 strain. Physiol Behav 51:979–85
50. Mondragón-Rodríguez S, Perry G, Luna-Muñoz J et al (2013) Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer’s disease and Down syndrome. Neuropathol Appl Neurobiol. doi:10.1111/nan.12084
51. Morley JE, Kumar VB, Bernardo AE et al (2000) Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides 21:1761–7
52. Morley JE, Farr SA, Flood JF (2002) Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem 78:125–38. doi:10.1006/nlme.2001.4047
53. Morley JE, Farr SA, Kumar VB, Armbrecht HJ (2012) The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer’s disease. Curr Pharm Des 18:1123–30
54. Pallas M, Camins A, Smith MA et al (2008) From aging to Alzheimer’s disease: unveiling “the switch” with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis 15:615–24
55. Perry G, Raina AK, Nunomura A et al (2000) How important is oxidative damage? Lessons from Alzheimer’s disease. Free Radic Biol Med 28:831–4
56. Piedrahita D, Hernández I, López-Tobón A et al (2010) Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer’s mice. J Neurosci 30:13966–76. doi:10.1523/JNEUROSCI. 3637-10.2010
57. Pimplikar SW (2009) Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol 41:1261–8. doi:10.1016/j.biocel.2008.12.015
58. Smith MA, Perry G, Richey PL et al (1996) Oxidative damage in Alzheimer’s. Nature 382:120–1. doi:10.1038/382120b0
59. Swomley AM, Förster S, Keeney JT et al (2013) Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim Biophys Acta. doi:10.1016/j.bbadis.2013.09.015
60. Takeda T (2009) Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem Res 34:639–59. doi:10.1007/s11064-009-9922-y
61. Takeda T, Hosokawa M, Takeshita S et al (1981) A new murine model of accelerated senescence. Mech Ageing Dev 17:183–94
62. Thinakaran G, Borchelt DR, Lee MK et al (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17:181–190
63. Verri M, Pastoris O, Dossena M et al (2012) Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer’s disease. Int J Immunopathol Pharmacol 25:345–53
64. Wisniewski HM, Wegiel J, Kotula L (1996) Review: David Oppenheimer Memorial Lecture 1995: some neuropathological aspects of Alzheimer’s disease and its relevance to other disciplines. Neuropathol Appl Neurobiol 22:3–11. doi:10.1111/j.1365-2990.1996.tb00839.x
65. Wolfe MS (2013) Toward the structure of presenilin/γ-secretase and presenilin homologs. Biochim Biophys Acta 1828:2886–97. doi:10.1016/j.bbamem.2013.04.015
66. Yagi H, Katoh S, Akiguchi I, Takeda T (1988) Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Brain Res 474:86–93
67. Zhu X, Raina AK, Perry G, Smith MA (2004) Alzheimer’s disease: the two-hit hypothesis. Lancet Neurol 3:219–26. doi:10.1016/S1474-4422(04)00707-0
68. Zhu X, Lee H, Perry G, Smith MA (2007) Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 1772:494–502. doi:10.1016/j.bbadis.2006.10.014